Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

ABT-199 (Venetoclax) and Purine Analogues as Novel Oral Drug Combination for Treatment of Relapsed/Refractory Acute Myeloid Leukemia: the ApoAML Trial

NCT05506332 is registered in ClinicalTrials.gov with University Hospital, Antwerp as lead sponsor.

NCT NCT05506332
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05506332 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
ABT-199 (Venetoclax) and Purine Analogues as Novel Oral Drug Combination for Treatment of Relapsed/Refractory Acute Myeloid Leukemia: the ApoAML Trial
Lead sponsor
University Hospital, Antwerp
Phase
Phase 1
Overall status
Recruiting
Start date
July 15, 2022
Completion date
December 31, 2026
Enrollment
10 (estimated)
Sites
2

Conditions

As the registry lists them; a condition with its own page is linked.

acute myeloid leukemia refractory, acute myeloid leukemia, in relapse